Feature | Antiplatelet and Anticoagulation Therapies | May 12, 2017

Delayed Use of Blood Thinners in AFib Patients Increased Dementia Risk

First large scale study of 76,000 patients shows impact of antiplatelet and anticoagulant agents on dementia risks

anticoagulants increase dementia risks

May 12, 2017 – A new study found that dementia rates increase with delays in starting anticoagulation treatment for atrial fibrillation (AFib or AF). The large study included more than 76,230 AF patients with no prior history of dementia that were treated with an antiplatelet or warfarin. The results were presented at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions, and show that warfarin, in particular, can increase the risk of dementia long-term.

AF, the most common heart arrhythmia, affects more than 2.7 million American adults and has been known to increase a person’s risk of stroke and death. Anticoagulants and antiplatelet agents, especially warfarin, are powerful stroke prevention interventions and are now being prescribed to millions worldwide.[1] However, there is often a delay in starting anticoagulants after the initial AF diagnosis due to a variety of reasons, including low risk of stroke, exploration of other treatment options like aspirin, older age, multiple comorbidities, and other factors.

The study included 76,230 AF patients who had no prior history of dementia or prior use of an anticoagulation treatment. Of these, 26,189 patients were ultimately treated with an antiplatelet (n=21,781) or warfarin anticoagulation (n=4,408). Time from AF diagnosis to the use of an antiplatelet agent or anticoagulation was studied at immediate start (less than 30 days from diagnosis), and delayed (after one year). The authors note that CHADS2 Vasc score can be used to identify those at highest risk of cognitive decline with a delay in therapy. The risk of dementia with a delay in low risk CHADS2 Vasc patients was 30 percent but increased significantly to 136 percent in high-risk CHADS2 Vasc patients. The authors also found that when the time period of delays were analyzed as a spectrum from less than 30 days, 31 days to one year, one to three years and longer than three years, there was a linear risk of dementia risk with the delays in warfarin initiation.

“Our results reinforce the importance of starting anticoagulation treatment as early as possible after being diagnosed with atrial fibrillation. We saw for the first time that waiting even just 30 days to initiate anticoagulation treatment can increase a patient’s long-term risk of developing dementia,” said T. Jared Bunch, M.D., director of heart rhythm research at Intermountain Medical Center Heart Institute and medical director for heart rhythm services for the Intermountain Healthcare system. “We want to ensure we’re doing everything possible to limit the risk of brain injury for our patients and our study not only shows the importance of early therapy but also shows the very limited role, if any, of aspirin for stroke prevention. In this study,the benefit was derived from using warfarin and we hope that newer anticoagulants that perform better than warfarin and are easier to start and use will further improve dementia risk.”

The authors of the study called for additional studies to fully understand how the risk of dementia increases over a longer period of time. They have recently launched a prospective study using dabigatran versus warfarin that will closely study cognitive changes over a two-year period. The growing use of these newer treatments like direct oral anticoagulants such as dabigatran, apixaban and rivaroxaban, are providing patients with more effective options and should also be studied to determine the risk of dementia.

Related Content:

Long-term Anti-clotting/antiplatelet Drug Combo in AFib Patients May Raise Risk of Dementia

Atrial Fibrillation Patients at Increased Risk of Dementia Regardless of Anticoagulation Use

Dementia Risk Increased for Afib Patients on Long-Term Warfarin Treatment

Researchers Find Link Between Early-Stage Brain and Heart Disease

Vascular Disease after Age 80 Associated with Greater Dementia Risk

Advantages and Disadvantages of Novel Oral Anticoagulants

 

For more information: www.HRSonline.org, www.hrssessions.org

References: 

1. A. Di Minno, G. Spadarella, T. Antonella, G. Di Minno. “Ensuring medication adherence with direct oral anticoagulant drugs. Lessons from adherence with vitamin K antagonists (VKAs).” Thrombosis Research, 2014, 133(5). DOI: 10.1016/j.thromres.2014.01.016 

2. T. Jared Bunch, Heidi T. May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Victoria Jacobs, Charles Mallender, Jeffrey S. Osborn, Scott M. Stevens, J. Peter Weiss and Scott C. Woller. HRS Heart Rhythm 2017 meeting session, “Anticoagulation for Atrial Fibrillation: Current Strategies and Device-Based Approaches: Dementia Rates Increase With Delays In Initiation of Anticoagulation Treatment for Atrial Fibrillation.” Presented May 12, 2017.

Related Content

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Aspirin Should Not Be Recommended for Healthy People Over 70
News | Antiplatelet and Anticoagulation Therapies | September 20, 2019
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk...
Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Overlay Init